FDA Drug Recalls

Recalls / Class III

Class IIID-1178-2023

Product

Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted before use, NDC 62935-753-75, Manufactured by: Tolmar Inc., Fort Collins, CO 80526, For Tolmar Therapeutics Inc., Fort Collins, CO 80526.

Brand name
Eligard
Generic name
Leuprolide Acetate
Route
Subcutaneous
NDCs
62935-223, 62935-753, 62935-303, 62935-453
FDA application
NDA021379
Affected lot / code info
Lot: 13635A1, Exp. 07/31/2024

Why it was recalled

Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.

Recalling firm

Firm
Tolmar, Inc.
Manufacturer
TOLMAR Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
701 Centre Ave, N/A, Fort Collins, Colorado 80526-1843

Distribution

Quantity
2990 cartons
Distribution pattern
Nationwide in the US.

Timeline

Recall initiated
2023-09-12
FDA classified
2023-09-27
Posted by FDA
2023-10-04
Terminated
2024-10-03
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1178-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Eligard · FDA Drug Recalls